Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?

Reyes, Amanda; Pharaon, Rebecca; Mohanty, Atish; Massarelli, Erminia

Reyes, Amanda; Pharaon, Rebecca; Mohanty, Atish; Massarelli, Erminia.

Afiliação

Reyes A; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.
Pharaon R; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.
Mohanty A; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.
Massarelli E; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.

Cancers (Basel) ; 15(12)2023 Jun 13.

Article em En | MEDLINE | ID: mdl-37370772

Palavras-chave

Axl signaling; EGFR mutated; EGFR resistance; HER2; HER3; MET amplification; antibody-drug conjugates; bispecific antibodies; cMet signaling; immunotherapy; non-small cell lung cancer; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google